On July 3, Sino Biopharmaceutical rose 4.76% in regular trading, trading at HK$4.79/share, with turnover of HK$92.32 million.

On the news front, the National Healthcare Security Administration recently published the list of drugs that passed the preliminary formal review for the basic medical insurance catalog and commercial insurance innovative drug catalog adjustment. The review results showed increased application volume, significantly improved pass rate, and a predominance of new drugs among applications. Combined with the first-ever introduction of a pre-application mechanism, the outcome fully demonstrates the catalog adjustment's continued tilt toward innovative drugs. CITIC Construction Investment issued a research note expressing optimism on relevant innovative drug companies' medical insurance access and commercial insurance incremental opportunities.

Additionally, the broader pharmaceuticals sector showed strength, with CSPC Pharma up 4.11%, Hansoh Pharma up 4.02%, Hengrui Pharma up 1.35%, Luye Pharma up 5.38%, and Haixi Pharma up 10.79%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)